NICE
Faslodex rejected by NICE for NHS breast cancer use
February 2, 2018Research and Development, Sales and Marketing AstraZeneca, Faslodex, NHS, NICE, UK, pharma
Bad news for breast cancer patients in the UK as the National Institute for Health and Care Excellence announces it …
NICE urges curbing the use of antibiotics for sore throats
January 26, 2018Medical Communications Antibiotics, NICE, biotech, drugs, pharma, pharmaceutical
In a study published by the BMJ a few years ago, it was found that antibiotics were prescribed in 60% …
NICE recommends for online and mobile depression programme for trial on NHS
January 24, 2018Research and Development Deprexis, NHS, NICE, app, depression, pharma
NICE has said that a new online and mobile app should be trialled on the NHS in the treatment of …
Top Ten most popular articles on Pharmafile.com this week
January 5, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, J&J, JJ, NICE, Pfizer, Spark Therapeutics, Valeant, top ten
Happy New Year from Pharmafile.com! We hope the first week of 2018 hasn’t been too rough. To the surprise of …
NICE recommends first overseas treatment for use on NHS with GSK ‘bubble baby’ gene therapy
January 4, 2018Sales and Marketing ADA-SCID, GSK, GlaxoSmithKline, NHS, NICE, Strimvelis, bubble baby, pharma
NICE has chalked up a new first in its assessment of treatments for use on the NHS, ruling that the …
NICE to take another look at Pfizer’s leukaemia drug
January 2, 2018Manufacturing and Production, Sales and Marketing NICE, Pfizer, biotech, drugs, pharma, pharmaceutical
Back in August of 2017, NICE rejected Pfizer’s Besponsa on cost-effectiveness grounds and the pharma giant was not best pleased. …
NICE recommends Novartis’ Extavia for MS, but knocks back a raft of other beta interferons
December 20, 2017Research and Development, Sales and Marketing Extavia, MS, NICE, Novartis, beta interferon, multiple sclerosis
NICE has revealed that it has passed draft guidance that recommends Novartis’ Extavia (interferon beta 1b) for the treatment of …
Novartis nets first acute myeloid leukaemia approval in Canada, but NICE says no
December 6, 2017Research and Development, Sales and Marketing Canada, NICE, Novartis, Rydapt, UK, acute myeloid leukaemia, leukaemia, pharma
Novartis is celebrating the news that its drug Rydapt (midostaurin) has been awarded marketing approval in Canada for the treatment …
NICE refuses Eisai’s breast cancer drug in new indication
November 28, 2017Manufacturing and Production, Sales and Marketing Cancer, Eisai, Halaven, NICE, breast cancer, pharma
NICE has announced that it has rejected Eisai’s Halaven (eribulin) through draft guidance advising not to use the drug in …
NHS England seals access deals with big pharma for breast cancer and MS
November 9, 2017Sales and Marketing Cancer, Mavenclad, Merck, NHS, NHS England, NICE, Perjeta, Roche, Simon Stevens, breast cancer, multiple sclerosis
NHS England has entered into a commercial agreement with Merck which aims to provide access to innovative treatments for both …
BMS agrees deal on Opdivo availability through Cancer Drugs Fund for head and neck cancer
October 13, 2017Sales and Marketing BMS, Bristol-Myers Squibb, CDF, Cancer Drugs Fund, NICE, opdivo, pharma, pharmaceutical
Thanks to successful negotiation of a managed access agreement, NICE has announced its recommendation of Bristol-Myers Squibb’s Opdivo (nivolumab) for …
NICE gives final draft guidance on two key cancer drugs
October 12, 2017Sales and Marketing Bayer, CDF, Cancer, Cancer Drugs Fund, Erivedge, NICE, Roche, Stivarga
NICE has announced it has published its final draft guidance for two cancer treatments, covering Bayer’s Stivarga (regorafenib) in the …
UK High Court rejects ABPI’s challenge to new NICE cost curbs
October 5, 2017Sales and Marketing ABPI, NHS, NHS England, NICE, legal, pharma, pharmaceutical
The ABPI has been knocked back by the UK High Court in its legal challenge to NICE over new drug …
Top Ten most popular articles on Pharmafile.com this week
September 29, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, EMA, FDA, HIV, J&J, JJ, Kevzara, Mylan, NICE, Sanofi, nash, top ten
It’s Friday, and it’s time for another round up of the most popular articles on pharmafile.com over the last seven …
Sanofi’s arthritis treatment Kevzara secures NICE recommendation
September 25, 2017Sales and Marketing Kevzara, NICE, Sanofi, pharma, pharmaceutical, rheumatoid arthritis, sarilumab
Sanofi, along with its speciality care global business unit Sanofi Genzyme, are celebrating the news that NICE has passed its …
Latest content
FibroFind appoints Lee Borthwick as CEO
